Dekabi Stem Cell Clinic in Gangnam, Seoul · Trusted Regenerative Medicine Over 22 Years

5.0 Patient Satisfaction

en-US

Dekabi Stem Cell ClinicHome
Book Consultation
Book Consultation
Patient Guide
SpecialtiesServicesDoctorsProgramsArticlesReviewsAbout UsContact Us
How Stem Cells Reduce Inflammation in Post-COVID Recovery?

Regenerative Medicine Guide

How Stem Cells Reduce Inflammation in Post-COVID Recovery?

Discover how stem cells reduce inflammation and support post-COVID recovery. Explore their healing potential in long COVID treatment. Learn more now!

Schedule a Consultation

Introduction: Post‑COVID inflammatory burden

Many individuals recovering from COVID‑19 continue to face persistent symptoms—fatigue, breathlessness, cognitive fog, joint/muscle pain, autonomic disturbances—that are increasingly attributed to sustained inflammation, immune dysregulation, microvascular damage and tissue injury. In effect, the acute viral assault may be over, but a chronic dysregulated inflammatory environment remains, impairing healing, causing fibrotic changes (especially in the lung), and affecting multi‑organ health.

Post‑COVID inflammatory burden

At the Dekabi Stem Cell Clinic, with over 22 years specialising in regenerative medicine, we view such post‑COVID inflammation as an ideal target for MSC‑based regenerative interventions: not only addressing the damage, but modulating the underlying inflammatory drivers. In what follows, I will outline how MSC therapy works mechanistically, then translate into how this is applied in post‑COVID recovery, and conclude with the unique advantages and considerations of the clinic’s approach.

Application to Post‑COVID Recovery

With the mechanistic foundations laid out, let’s translate this into how MSC therapy can help in the specific context of post‑COVID inflammatory sequelae, and why a specialised centre such as Dekabi is well‑suited to apply it.

Inflammation in Long‑COVID: major targets

Some of the principal inflammatory and injury‑driven targets in post‑COVID patients include:

  • Pulmonary residual inflammation/fibrosis: Even after viral clearance, many patients have lingering lung inflammation, interstitial changes and fibrotic remodeling.
  • Endothelial/microvascular injury: COVID‑19 is known to cause microthrombi, endothelial disruption and microvascular rarefaction, which perpetuate inflammation and organ dysfunction.
  • Neurological/post‑viral cognitive symptoms: Neuroinflammation, microglial activation, damage to blood‑brain‑barrier and small‑vessel injury may all persist.
  • Cardiac/muscular fatigue: Persistent inflammation of myocardium or skeletal muscle, chronic oxidative stress and mitochondrial dysfunction contribute to post‑exertional fatigue.
  • Immune dysregulation/autoimmunity: Some patients develop new autoimmune phenomena or persistent immune activation even after the acute phase.
  • Systemic low‑grade inflammation: Elevated markers (CRP, IL‑6, TNF‑α) may persist, driving symptoms like fatigue, joint/muscle pain, autonomic issues.

By targeting these underlying mechanisms, MSC therapy offers a “regenerative” strategy rather than mere symptomatic relief.

How MSCs address post‑COVID inflammation

Taking each major target in turn:

  • Lung & fibrosis: MSCs can home to damaged lung tissue, reduce pro‑inflammatory macrophage activation, secrete antifibrotic and angiogenic factors, reduce oxidative stress in alveolar and endothelial cells, and stimulate repair of microvasculature. Thus, persistent lung inflammation and early fibrotic changes may be mitigated.
  • Microvascular/endothelial injury: MSC‑secreted factors promote endothelial repair and angiogenesis, while regulating immune cell‑endothelium interaction and reducing microthrombi‑driven inflammation.
  • Neurological sequelae: In neuroinflammation, MSCs modulate microglial activation, reduce pro‑inflammatory cytokines in the CNS, transfer mitochondria/vesicles to damaged neurons, and support blood‑brain‑barrier repair. This may ameliorate brain fog, neuropathy and cognitive symptoms.
  • Muscle/cardio fatigue: MSCs mitigate oxidative stress and mitochondrial dysfunction in muscle and cardiac tissue, reduce persistent inflammation, and promote recovery of tissue function rather than simply suppressing symptoms.
  • Immune dysregulation/autoimmunity: By shifting immune balance (enhancing Tregs, reducing Th17, modulating B‑cells), MSCs help restore immune homeostasis and lower risk of post‑viral autoimmune phenomena.
  • Systemic inflammation: Through widespread paracrine effects, MSC therapy acts as a systemic “inflammation regulator,” reducing chronic cytokine/chemokine burden, promoting detoxification of oxidised molecules, and improving patient vitality.

Personalized therapy at Dekabi Stem Cell Clinic

Personalized therapy

At Dekabi Stem Cell Clinic, we apply these insights in a tailored, patient‑centred model:

  • Patient assessment: We evaluate residual inflammation markers (cytokines, complement, endothelial biomarkers), imaging (lung CT or MRI if needed), microvascular/endothelial function, mitochondrial/oxidative stress indicators, and symptom profiling.
  • Personalised MSC protocol: Based on the profile, we design a therapy schedule: source (autologous or allogeneic MSCs), delivery route (IV vs organ‑targeted), cell dose, and number of treatments.
  • Adjunctive treatments: Because inflammation and tissue damage overlap, we integrate detoxification programs, energy medicine (metabolic support, mitochondrial rescue), functional neurosurgery or functional regenerative interventions, nutritional support, anti‑aging therapies (since prolonged inflammation accelerates ageing) and physical rehabilitation.
  • Monitoring & follow‑up: We monitor inflammatory markers, imaging improvements (for lung/endothelium), functional metrics (exercise tolerance, cognition, autonomic function), and adjust therapy accordingly.

The goal is not simply “symptom relief” but long‑term regeneration—healing the damage, recalibrating the immune system, restoring energy and vitality.

Unique Advantages & Considerations for Post‑COVID MSC Therapy

Why choose a specialised centre like Dekabi?

  • Expertise & experience: With over 34 years in medicine and 22 years dedicated to stem cell therapy, our team (led by Dr Eun Young Baek) has a deep understanding of regenerative medicine nuanced for complex chronic conditions.
  • Regenerative + anti‑aging focus: Post‑COVID inflammation overlaps with accelerated ageing and multi‑organ stress; our approach bridges regenerative therapy, anti‑aging interventions and functional restorative medicine.
  • Personalised care: Many clinics apply “one size fits all” stem cell protocols; we tailor cell source, dose, adjuncts and rehabilitation to the individual’s residual profile, thereby enhancing outcomes.
  • Holistic support: Addressing detoxification, mitochondrial health, nervous system function, endocrine/metabolic balance and psychosocial recovery is as important as the cell therapy itself.
  • Safety and monitoring: We adhere to rigorous standards, assessing inflammation, infection risk, immune status, and carefully selecting patients for optimal benefit.

Considerations and challenges

  • Timing: The optimal timing for MSC therapy post‑COVID is still being studied. In general, once acute infection has resolved and no contraindication exists, the “window of opportunity” is in the sub‑acute/chronic phase where inflammation persists but before irreversible fibrosis sets in.
  • Patient selection: Not all post‑COVID symptoms are inflammation‑mediated; some may be deconditioning, autonomic dysfunction, or unrelated comorbidities. Thorough assessment is key to identify those who will benefit most from MSC therapy.
  • Dose and delivery: Scientific consensus on optimal dose, cell source (bone‑marrow vs adipose vs umbilical cord), delivery route is still evolving. At Dekabi, we use evidence‑informed protocols and adjust based on patient response.
  • Regulatory/ethical considerations: Stem cell therapy is regulated; ensuring accredited sourcing, cell handling, patient consent and long‑term follow‑up is imperative.
  • Outcome variability: While many patients show significant improvement, individual responses vary depending on extent of initial damage, comorbidities, age, residual viral or endothelial injury and overall health. Setting realistic expectations is part of our process.
  • Integration with rehabilitation: Stem cell therapy is not a stand‑alone “magic bullet.” Rehabilitation, nutrition, physical activity, cognitive support, autonomic function restoration are crucial for full benefit.

A Suggested Treatment Pathway for Post‑COVID Inflammation at Dekabi

Here is a hypothetical but representative pathway for a post‑COVID patient presenting with persistent fatigue, breathlessness on exertion, cognitive fog and elevated inflammatory markers.

  1. Initial evaluation

    • Clinical history: date of COVID infection, severity, hospitalisation, residual respiratory/cardiac/neurologic symptoms.

    • Laboratory markers: inflammatory cytokines (IL‑6, TNF‑α), oxidative stress markers, endothelial biomarkers, autoantibody screen.

    • Imaging: lung CT (if breathlessness), echocardiography (if cardiac/palpitations), brain/MRI (if neuro symptoms).

    • Functional tests: pulmonary function (spirometry, diffusion capacity), 6‑minute walk test, cognitive screening, autonomic testing.

    • Metabolic/microvascular assessment: mitochondrial function, oxidative stress, microvascular endothelial function.

  2. Personalised MSC therapy planning

    • Choice of MSC source (e.g., allogeneic umbilical‑cord derived MSCs vs autologous).

    • Dose and schedule (e.g., infusion over 1–3 sessions, possibly organ‑targeted if lung predominant).

    • Pre‑conditioning of MSCs (some centres pre‑condition under hypoxia/inflammatory cues to enhance effect).

    • Delivery route (primarily intravenous + targeted organ infusion if needed).

  3. Adjunctive regenerative support

    • Detox programme: support of liver/kidney/microvascular system to clear inflammatory metabolites.

    • Mitochondrial/energy support: therapies aimed at restoring mitochondrial function, reducing oxidative stress.

    • Anti‑aging/anti‑fibrotic support: protocols (e.g., specific growth factors, supplementation, lifestyle interventions) aimed at reversing accelerated ageing from chronic inflammation.

    • Rehabilitation: respiratory physiotherapy, cardiac rehabilitation if needed, cognitive rehabilitation, autonomic retraining.

    • Nutritional and metabolic optimisation: addressing persistent insulin resistance, dyslipidaemia, microvascular health.

  4. Treatment delivery & monitoring

    • Administration of MSC therapy under sterile, certified conditions.

    • Close monitoring for immediate reactions, infectious complications, immune changes.

    • Follow‑up at 1 month, 3 months, 6 months: repeat functional tests, inflammatory/oxidative markers, imaging as indicated.

    • Adjustments: if response suboptimal, booster MSC session, or switch adjunctive focus (e.g., more neuro support, more endothelial repair).

  5. Long‑term maintenance & prevention

  • Encouraging ongoing lifestyle: exercise (especially aerobic + strength training), anti‑inflammatory diet, stress management, sleep optimisation.
  • Periodic check‑ups for immune/inflammatory markers, microvascular health, organ function (lung, heart, neurological).
  • Early intervention for any emerging signs of fibrotic progression or organ decline.
  • Patient education: recognising signs of “flare” and returning for timely intervention before damage becomes irreversible.

wellness

More Medical Articles

Continue exploring our evidence-informed stem cell and longevity guides.

View All
Safety, Ethics, and Innovation: Why Dekabi is the Most Trusted Name in Korean Stem Cell Therapy

Safety, Ethics, and Innovation: Why Dekabi is the Most Trusted Name in Korean Stem Cell Therapy

For international patients, choosing a stem cell clinic is a high-stakes decision often clouded by skepticism and regulatory confusion. This article positions Dekabi Stem Cell Clinic not just as a medical provider, but as a global leader in ethical regenerative science.

Learn More

Learn More
The Shift to Autologous Stem Cell Therapy in Korean Pain Care

The Shift to Autologous Stem Cell Therapy in Korean Pain Care

Discover why Autologous Stem Cell Therapy is the new standard for pain care in Korea. Compare costs, outcomes, and root-cause healing at Dekabi Clinic.

Learn More

Learn More
What to Expect from Stem Cell Therapy for Diabetes Patients?

What to Expect from Stem Cell Therapy for Diabetes Patients?

Explore what to expect from stem cell therapy for diabetes patients—benefits, process, and outcomes of this innovative treatment. Learn more today.

Learn More

Learn More

Medical Clinic

Dekabi Stem Cell Clinic in Gangnam, Seoul (249-6 Nonhyeon-dong / 626 Eonju-ro) provides personalized autologous stem cell therapy, chronic pain care, anti-aging, and cellular detoxification.

Treatments

SpecialtiesServicesMedical TeamClinical ProgramsMedical Articles

Patient Guide

About UsHow It WorksPatient ReviewsPress & Media

Information & Legal

Contact & LocationSite SearchPrivacy PolicyRefund & Cancellation PolicyTerms of Use

© 2026 Dekabi Stem Cell Clinic. All rights reserved.

Individual clinical results may vary. Please consult Dr. Eun Young Baek and our medical team for personalized evaluation.